ClinicalTrials.Veeva

Menu
K

Kent and Canterbury Hospital | Renal Research Delivery Team

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

cyclophosphamide
Dexamethasone
doxorubicin hydrochloride
vincristine sulfate
etoposide
prednisone
Daratumumab
Cyclophosphamide
mitoxantrone hydrochloride
vinblastine sulfate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 62 total trials

A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)

This study aims to examine the efficacy and safety of obexelimab in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).

Enrolling
Warm Autoimmune Hemolytic Anemia
Other: Placebo
Drug: Obexelimab

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free sur...

Active, not recruiting
Smoldering Multiple Myeloma
Drug: Daratumumab SC: daratumumab + rHuPH20

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in comb...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Talquetamab

The Cardamon trial is a phase 2 trial using the standard chemotherapy drugs cyclophosphamide and dexamethasone in combination with a new drug called...

Active, not recruiting
Multiple Myeloma
Procedure: Autologous Stem Cell Transplant (ASCT)
Drug: Consolidation with 4 cycles of CarCyDex

The purpose of this study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising...

Active, not recruiting
Prostate Cancer
Drug: Placebo oral tablet
Drug: Luteinizing Hormone-Releasing Hormone Analog

Randomized, controlled, parallel groups, open-label, blinded end-point assessment, multicenter study, comparing the effects of a low glucose peritone...

Enrolling
End Stage Renal Disease
Drug: XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght
Drug: 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution

The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a...

Enrolling
B-cell Malignancies
Drug: Zanubrutinib
Drug: Tislelizumab

The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclo...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Pomalidomide

The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available t...

Enrolling
Polycythemia Vera
Drug: Ruxolitinib
Drug: Hydroxycarbamide

Trial Title:FiTNEss (UK-MRA Myeloma XIV) - Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple MyelomaOverview...

Enrolling
Multiple Myeloma
Drug: R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm
Drug: R2: Lenalidomide plus placebo maintenance

Trial sponsors

University College London (UCL) logo
Janssen (J&J Innovative Medicine) logo
U
I
L
U
BeiGene logo
C
E
Gilead Sciences logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems